[KLCC] QoQ Cumulative Quarter Result on 31-Mar-2019 [#1]

Stock
[KLCC] KLCC PROP&REITS-STAPLED SEC
Announcement Date
07-May-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
31-Mar-2019 [#1]
Profit Trend
QoQ- -74.62%
YoY- 1.82%
Quarter Report
Latest QR
Upcoming QR
KLCC's Result
KLCC's Financial Summary
View:
Show?
Cumulative Result
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
Revenue 1,423,021 1,058,060 704,539 353,446 1,405,941 1,039,593 690,113 61.79%
PBT 1,071,321 708,853 473,617 239,595 964,093 701,138 466,622 73.77%
Tax -125,650 -78,358 -53,291 -26,965 -125,173 -76,303 -51,737 80.38%
NP 945,671 630,495 420,326 212,630 838,920 624,835 414,885 72.93%
-
NP to SH 790,151 545,739 364,334 183,958 724,914 541,253 359,819 68.70%
-
Tax Rate 11.73% 11.05% 11.25% 11.25% 12.98% 10.88% 11.09% -
Total Cost 477,350 427,565 284,213 140,816 567,021 414,758 275,228 44.20%
-
Net Worth 13,215,038 13,124,771 13,106,718 13,088,664 13,088,664 13,070,610 13,052,557 0.82%
Dividend
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
Div 686,026 476,607 317,738 158,869 667,973 471,191 314,127 68.08%
Div Payout % 86.82% 87.33% 87.21% 86.36% 92.15% 87.06% 87.30% -
Equity
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
Net Worth 13,215,038 13,124,771 13,106,718 13,088,664 13,088,664 13,070,610 13,052,557 0.82%
NOSH 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 0.00%
Ratio Analysis
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
NP Margin 66.46% 59.59% 59.66% 60.16% 59.67% 60.10% 60.12% -
ROE 5.98% 4.16% 2.78% 1.41% 5.54% 4.14% 2.76% -
Per Share
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
RPS 78.82 58.61 39.03 19.58 77.88 57.58 38.23 61.77%
EPS 43.77 30.23 20.18 10.19 40.15 29.98 19.93 68.71%
DPS 38.00 26.40 17.60 8.80 37.00 26.10 17.40 68.08%
NAPS 7.32 7.27 7.26 7.25 7.25 7.24 7.23 0.82%
Adjusted Per Share Value based on latest NOSH - 1,805,333
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
RPS 78.82 58.61 39.03 19.58 77.88 57.58 38.23 61.77%
EPS 43.77 30.23 20.18 10.19 40.15 29.98 19.93 68.71%
DPS 38.00 26.40 17.60 8.80 37.00 26.10 17.40 68.08%
NAPS 7.32 7.27 7.26 7.25 7.25 7.24 7.23 0.82%
Price Multiplier on Financial Quarter End Date
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
Date 31/12/19 30/09/19 28/06/19 29/03/19 31/12/18 28/09/18 29/06/18 -
Price 7.90 8.07 7.77 7.76 7.66 7.60 8.00 -
P/RPS 10.02 13.77 19.91 39.64 9.84 13.20 20.93 -38.72%
P/EPS 18.05 26.70 38.50 76.16 19.08 25.35 40.14 -41.21%
EY 5.54 3.75 2.60 1.31 5.24 3.94 2.49 70.17%
DY 4.81 3.27 2.27 1.13 4.83 3.43 2.18 69.23%
P/NAPS 1.08 1.11 1.07 1.07 1.06 1.05 1.11 -1.80%
Price Multiplier on Announcement Date
31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 30/06/18 CAGR
Date 23/01/20 11/11/19 20/08/19 07/05/19 24/01/19 13/11/18 15/08/18 -
Price 7.98 7.99 7.87 7.86 7.90 7.66 7.62 -
P/RPS 10.12 13.63 20.17 40.15 10.14 13.30 19.93 -36.27%
P/EPS 18.23 26.43 39.00 77.14 19.67 25.55 38.23 -38.88%
EY 5.48 3.78 2.56 1.30 5.08 3.91 2.62 63.33%
DY 4.76 3.30 2.24 1.12 4.68 3.41 2.28 63.12%
P/NAPS 1.09 1.10 1.08 1.08 1.09 1.06 1.05 2.51%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment